for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

DarioHealth Corp

DRIO.OQ

Latest Trade

0.25USD

Change

-0.00(-0.79%)

Volume

14,175

Today's Range

0.25

 - 

0.26

52 Week Range

0.24

 - 

1.32

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
0.25
Open
0.25
Volume
14,175
3M AVG Volume
1.92
Today's High
0.26
Today's Low
0.25
52 Week High
1.32
52 Week Low
0.24
Shares Out (MIL)
43.68
Market Cap (MIL)
11.06
Forward P/E
-0.61
Dividend (Yield %)
--

Next Event

Q3 2019 DarioHealth Corp Earnings Release

Latest Developments

More

Dance Biopharm Partners With DarioHealth To Expand Access To Digital Therapeutics Platform For Patients With Chronic Diseases

Dariohealth QTRLY Loss Per Share $0.13

DarioHealth Launches New Blood Pressure Monitoring System

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About DarioHealth Corp

DarioHealth Corp, formerly Labstyle Innovations Corp, is a digital health (mHealth) company. The Company is engaged in developing and commercializing a technology providing consumers with laboratory-testing capabilities using smart phones and other mobile devices. The Company's product, Dario, also known as Dario Smart Diabetes Management Solution, is a mobile, real-time, cloud-based, diabetes management solution based on a software application combined with a pocket-sized, blood glucose monitoring device, Dario Smart Meter. The Dario product is a digital diabetes management solution utilizing its technology delivered through a software application available for iPhone or Android and cloud-based data services with a blood glucose monitoring system device. Dario allows users to record, analyze, transmit and store various data points, such as glucose level, insulin and carbohydrate intake. It markets the Dario Smart Diabetes Management Solution in the Netherlands and New Zealand.

Industry

Biotechnology & Drugs

Contact Info

8 Hatokhen St.

+972.3.6222929

http://mydario.com

Executive Leadership

Yoav Shaked

Chairman of the Board

Olivier Jarry

President and Chief Commercial Officer

Erez Raphael

Chief Executive Officer, Director

Zvi Ben-David

Chief Financial Officer, Treasurer, Secretary

Dror Bacher

Chief Operating Officer

Key Stats

2.00 mean rating - 2 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.0K

2017

0.0K

2018

0.0K

2019(E)

0.0K
EPS (USD)

2016

-2.090

2017

-1.640

2018

-0.780

2019(E)

-0.415
Price To Earnings (TTM)
--
Price To Sales (TTM)
1.48
Price To Book (MRQ)
1.78
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-368.17
Return on Equity (TTM)
-193.92

Latest News

Latest News

BRIEF-Dariohealth Corp Says Selling Stockholders May Offer From Time To Time Up To 8.5 Mln shares

* DARIOHEALTH CORP SAYS SELLING STOCKHOLDERS MAY OFFER FROM TIME TO TIME UP TO 8.5 MILLION SHARES OF CO'S COMMON STOCK - SEC FILING Source text for Eikon: (http://bit.ly/2Fkuvtb) Further company coverage:

BRIEF-DarioHealth Receives U.S. FDA Clearance For iPhone 7, 8 And iPhone X Smart Glucose Meter

* DARIOHEALTH RECEIVES U.S. FDA CLEARANCE FOR IPHONE 7, 8 AND IPHONE X SMART GLUCOSE METER Source text for Eikon: Further company coverage:

BRIEF-DarioHealth Reports Fourth Quarter And Year End 2017 Results

* DARIOHEALTH REPORTS FOURTH QUARTER AND YEAR END 2017 RESULTS

BRIEF-DarioHealth Says Qtrly Reports On Form 10-Q For Quarter Ended March 30, 2017, June 30, 2017 And Sept 30, 2017 Should No Longer Be Relied Upon​

* DARIOHEALTH - QTRLY REPORTS ON FORM 10-Q FOR QUARTER ENDED MARCH 30, 2017, JUNE 30, 2017 AND SEPT 30, 2017 FILED WITH SEC SHOULD NO LONGER BE RELIED UPON

BRIEF-Dariohealth Launches Sales Of Dario Blood Glucose Monitoring System On Amazon Prime

* DARIOHEALTH LAUNCHES SALES OF DARIO™ BLOOD GLUCOSE MONITORING SYSTEM ON AMAZON PRIME

BRIEF-DarioHealth Wins Key Contract In Clinical Study

* DARIOHEALTH WINS KEY CONTRACT ENSURING ITS PLATFORM TO BE UTILIZED IN CLINICAL STUDY

BRIEF-Dariohealth - ‍ Received Therapeutic Goods Administration Mark For Its Lightning-Enabled Version Of Dario Blood Glucose Monitoring System

* DARIOHEALTH - RECEIVED THERAPEUTIC GOODS ADMINISTRATION MARK FOR ITS LIGHTNING-ENABLED VERSION OF DARIO BLOOD GLUCOSE MONITORING SYSTEM IN AUSTRALIA

BRIEF-Dariohealth Corp Q3 revenue $1.375 million

* Qtrly basic and diluted loss per share $0.30 Source text for Eikon: Further company coverage:

BRIEF-DarioHealth says selling stockholders may offer from time to time up to 2.9 mln shares of common stock

* DarioHealth Corp - selling stockholders may offer from time to time up to 2.9 million shares of co's common stock - SEC filing Source text: (http://bit.ly/2hQHQQg) Further company coverage:

BRIEF-DarioHealth launches into the German diabetes market

* DarioHealth Corp - expects launch into German market to help company reach its Q4 revenue goals and FY2017 annual milestones Source text for Eikon: Further company coverage:

BRIEF-Dariohealth raises $4.28 mln through private placement offerings

* Dariohealth raises $4.28 million through private placement offerings

BRIEF-DarioHealth Q2 loss per share $ 0.43

* DarioHealth Corp - qtrly net loss per share $ 0.43 Source text for Eikon: Further company coverage:

BRIEF-DarioHealth partners with Byram Healthcare

* Dariohealth corp - expanding its insurance coverage provider network by entering into a strategic agreement with byram healthcare

BRIEF-Dariohealth announces strategic partnership with CCS Medical

* Dariohealth announces strategic partnership with CCS Medical

BRIEF-Dariohealth recieves "first choice" recognition in 3 UK regions

* Dariohealth corp - CCGS in three UK regions have named dario blood glucose monitoring system first choice for all patients with type 1 diabetes Source text for Eikon: Further company coverage:

BRIEF-DarioHealth Q1 earnings per share $ 0.45

* Qtrly earnings per share $ 0.45 Source text for Eikon: Further company coverage:

BRIEF-Dariohealth expands global presence with direct-to-consumer launch in U.K.

* Dariohealth expands global presence with direct-to-consumer launch in U.K. Source text for Eikon: Further company coverage:

BRIEF-DarioHealth Corp announces proposed public offering of common stock

* DarioHealth Corp. announces proposed public offering of common stock

BRIEF-Ourcrowd Digital reports 13.1 pct stake in Dariohealth Corp

* Ourcrowd Digital Health L.P. reports 13.1 percent stake in Dariohealth Corp as of Jan 9 2017 - SEC filing

BRIEF-Dariohealth commenced private placement offering of up to $5.1 mln of securities

* On Jan 9, co commenced private placement offering of up to $5.1 million of co's securities, consisting of up to 1.8 million shares Source text for Eikon: Further company coverage:

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up